CN113143791A - Compound injection with whitening and anti-aging effects and preparation method thereof - Google Patents
Compound injection with whitening and anti-aging effects and preparation method thereof Download PDFInfo
- Publication number
- CN113143791A CN113143791A CN202110534448.1A CN202110534448A CN113143791A CN 113143791 A CN113143791 A CN 113143791A CN 202110534448 A CN202110534448 A CN 202110534448A CN 113143791 A CN113143791 A CN 113143791A
- Authority
- CN
- China
- Prior art keywords
- whitening
- compound injection
- effects
- aging
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 44
- 238000002347 injection Methods 0.000 title claims abstract description 44
- 239000007924 injection Substances 0.000 title claims abstract description 44
- 230000002087 whitening effect Effects 0.000 title claims abstract description 37
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 20
- 230000032683 aging Effects 0.000 claims abstract description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 46
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 32
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 30
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- 229940088594 vitamin Drugs 0.000 claims description 18
- 229930003231 vitamin Natural products 0.000 claims description 18
- 235000013343 vitamin Nutrition 0.000 claims description 18
- 239000011782 vitamin Substances 0.000 claims description 18
- 239000008151 electrolyte solution Substances 0.000 claims description 17
- 239000011259 mixed solution Substances 0.000 claims description 17
- 235000005152 nicotinamide Nutrition 0.000 claims description 17
- 239000011570 nicotinamide Substances 0.000 claims description 17
- 229960003966 nicotinamide Drugs 0.000 claims description 17
- 235000011187 glycerol Nutrition 0.000 claims description 16
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 15
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 108010024636 Glutathione Proteins 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- 229960003180 glutathione Drugs 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- 229920002643 polyglutamic acid Polymers 0.000 claims description 15
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 14
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 14
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 13
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 13
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 13
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 13
- 229940116977 epidermal growth factor Drugs 0.000 claims description 13
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 13
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 13
- 239000000600 sorbitol Substances 0.000 claims description 13
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 13
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 13
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 12
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 12
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 12
- 229920002674 hyaluronan Polymers 0.000 claims description 12
- 229960003160 hyaluronic acid Drugs 0.000 claims description 12
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 12
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 230000001804 emulsifying effect Effects 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 8
- 229930003268 Vitamin C Natural products 0.000 claims description 8
- 235000019154 vitamin C Nutrition 0.000 claims description 8
- 239000011718 vitamin C Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims description 5
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 238000007599 discharging Methods 0.000 claims description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000001103 potassium chloride Substances 0.000 claims description 5
- 235000011164 potassium chloride Nutrition 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000000176 sodium gluconate Substances 0.000 claims description 5
- 235000012207 sodium gluconate Nutrition 0.000 claims description 5
- 229940005574 sodium gluconate Drugs 0.000 claims description 5
- 239000001540 sodium lactate Substances 0.000 claims description 5
- 229940005581 sodium lactate Drugs 0.000 claims description 5
- 235000011088 sodium lactate Nutrition 0.000 claims description 5
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 abstract description 16
- 230000003750 conditioning effect Effects 0.000 abstract description 8
- 230000006870 function Effects 0.000 abstract description 8
- 210000004927 skin cell Anatomy 0.000 abstract description 8
- 230000037303 wrinkles Effects 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 230000001815 facial effect Effects 0.000 abstract description 5
- 230000003020 moisturizing effect Effects 0.000 abstract description 5
- 239000011148 porous material Substances 0.000 abstract description 5
- 238000005562 fading Methods 0.000 abstract description 4
- 230000004089 microcirculation Effects 0.000 abstract description 4
- 230000019522 cellular metabolic process Effects 0.000 abstract description 3
- 230000003716 rejuvenation Effects 0.000 abstract description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 11
- 230000004060 metabolic process Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 6
- 235000001968 nicotinic acid Nutrition 0.000 description 6
- 229960003512 nicotinic acid Drugs 0.000 description 6
- 239000011664 nicotinic acid Substances 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- -1 sulfur radicals Chemical class 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 108700022290 poly(gamma-glutamic acid) Proteins 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 2
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229920006017 homo-polyamide Polymers 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 235000013557 nattō Nutrition 0.000 description 2
- 230000000955 neuroendocrine Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000194035 Lactococcus lactis Species 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- HDTRYLNUVZCQOY-BTLHAWITSA-N alpha,beta-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-BTLHAWITSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a compound injection with whitening and anti-aging effects and a preparation method thereof. The facial mask mainly has the functions of shrinking pores, fading fine wrinkles, moisturizing and rejuvenating skin, has a full outline and a three-dimensional face, and has the effects of improving skin cell metabolism, conditioning skin microcirculation, conditioning facial qi and blood, beautifying, resisting aging and whitening.
Description
Technical Field
The invention relates to the technical field of compound injection, in particular to compound injection with whitening and anti-aging effects and a preparation method thereof.
Background
With the improvement of living standard, people pay more and more attention to aging problems and explore various whitening and anti-aging methods. Aging is also called aging, and generally refers to the phenomenon that after a living body is matured under normal conditions, the living body is aged, the function of the living body is reduced, the internal environment stability and the emergency ability are reduced, the structure and components gradually degenerate, and the living body tends to die and is irreversible. As bone tissues of a skeletal system age, bone becomes brittle and is easy to fracture, and the wound healing is slow; muscle atrophy; the conduction of the nervous system becomes slow, the memory declines, and the reaction is reduced; aging is also often accompanied by changes in the cardiovascular system, increased heart volume, and arterial vessel degeneration.
For aging studies, hundreds of theories have been proposed so far, and the main theories include a genetic programming theory, a cell mutation theory, a fault catastrophe theory, a free radical theory, a cross-linking theory, a neuroendocrine theory, an immunosenescence theory and the like. The neuroendocrine theory considers that hypothalamus-pituitary gland-adrenal gland are the main biological clock for regulating the aging process, and the neuroendocrine system is known to regulate the early development, growth, reproduction and metabolic functions of human body, and the change of the endocrine function can influence the aging process. The theory of immunosenescence considers that the immune function of the body is reduced along with the age of an individual, and the incidence rate of autoimmune diseases is also increased along with the aging of the body, so that the reduction of the immune function is considered to be closely related to the aging.
With the development of economy, the pace of work and life is faster and faster, the mental stress is larger and larger, and in addition to the damage of various factors such as bad living habits, bad environments, ultraviolet rays, incorrect skin care and the like to the skin, more and more people are troubled by the comprehensive problem of skin condition disorder such as dryness, roughness, inelasticity, dull complexion, full face, tiredness, roughness, large pores and the like, although skin care products on the market are very abundant, the comprehensive problem can not be well solved. In view of the related technical problems, no effective solution has been proposed at present.
Disclosure of Invention
The invention provides a compound injection with whitening and anti-aging effects and a preparation method thereof aiming at solving the technical problems in the prior art, and aims to mainly play roles in shrinking pores, fading fine wrinkles, moisturizing skin, plumping outline and making face three-dimensional, and have the effects of improving skin cell metabolism, conditioning skin microcirculation, conditioning facial qi and blood, beautifying, anti-aging and whitening.
In order to achieve the purpose, the invention provides the following technical scheme: the compound injection with the effects of whitening and resisting ageing comprises, by weight, vitamin C12-40%, glutathione 12-30%, nicotinamide 10-25%, nonapeptide-110-24%, mannitol 1-6%, sorbitol 1-5%, high methoxyl pectin 1-2%, propylene glycol alginate 1-3%, trehalose 1-3%, glycerol 2-16%, electrolyte solution 6-20%, epidermal growth factor 1-2%, polyglutamic acid 1-3%, sodium hyaluronate 1-2%, and hydrolyzed hyaluronic acid 1-2%.
Vitamin C, also called L-ascorbic acid, is a water-soluble vitamin. Vitamin C in food is absorbed by the upper small intestine of human body. Once absorbed, it distributes to all water-soluble structures in the body, with about 1500mg vitamin C in the vitamin C metabolically active pool in normal adults, with a peak storage peak of 3000mg vitamin C. Under normal conditions, most of vitamin C is metabolized and decomposed into oxalic acid in vivo or combined with sulfuric acid to generate ascorbic acid-2-sulfuric acid which is discharged by urine; the other part can be directly discharged out of the body by urine.
Glutathione is a peptide naturally synthesized in human cytoplasm, consists of glutamic acid, cysteine and glycine, contains sulfur radicals, is widely distributed in various organs of a body, plays an important role in maintaining the biological functions of cells, can activate various enzymes, thereby promoting the metabolism of sugar, fat and protein and influencing the metabolic process of the cells. It can be combined with free radical in vivo via sulfur radical, and can be converted into easily metabolized acid substance, thereby accelerating free radical excretion, and is helpful for relieving adverse side effects of chemotherapy and radiotherapy, and has no obvious influence on the curative effects of chemotherapy and radiotherapy. It can protect the functions of liver such as synthesis, detoxification, hormone inactivation and the like, promote the metabolism of cholic acid, and is beneficial to the absorption of fat, fat-soluble vitamins and the like by the digestive tract.
Niacinamide is a water-soluble vitamin and is a member of the vitamin B group. Nicotinic acid can be converted into nicotinamide in vivo, and although both compounds have vitamin effects, nicotinamide has less pharmacology and toxicity than nicotinic acid, and the effects are generated in the conversion process of nicotinic acid. Thus niacinamide also does not reduce cholesterol or cause flushing of the face like niacin. When the daily dose of the medicine is more than 3g for adults, the medicine has toxicity to the liver. In cells, nicotinic acid is used to synthesize Nicotinamide Adenine Dinucleotide (NAD) and Nicotinamide Adenine Dinucleotide Phosphate (NADP), while the conversion pathway for nicotinamide is very similar to that of nicotinic acid. NAD + and NADP + are coenzymes for a variety of enzymatic redox reactions.
Nonapeptide-1 is a biomimetic peptide, which has a good match with MC1 receptor on melanocyte, and thus can be used as an antagonist of melanocyte stimulating hormone to competitively bind with MC1 receptor and prevent tyrosinase from being further activated to produce melanin.
Mannitol is a common dehydrating agent with permeability, and can improve the osmotic pressure of blood plasma, promote water in tissues such as eyes, brain, cerebrospinal fluid and the like to enter blood vessels, and relieve the edema of local tissues; mannitol can also increase blood volume, increase pressure of glomerulus and capillary, increase osmotic pressure concentration in renal tubule, and promote diuresis; mannitol has good therapeutic effect on intracranial hypertension caused by trauma.
Sorbitol is used for reducing the intraocular pressure, the intracranial pressure and the volume of cerebrospinal fluid and the pressure thereof by mainly increasing the plasma osmotic pressure and leading water in tissues, particularly eyes, brains, cerebrospinal fluid and the like to enter blood vessels so as to relieve the edema of the tissues.
Trehalose is a non-reducing sugar composed of two glucose molecules with 1, 1-glycosidic bonds, has 3 isomers, namely trehalose (alpha ), isophyiosaccharide (beta ) and neotrehalose (alpha, beta), and has non-specific protective effects on various bioactive substances.
The colorless, sweet, clear and viscous liquid of glycerin can absorb moisture from the air, and also can absorb hydrogen sulfide, hydrogen cyanide and sulfur dioxide. Insoluble in benzene, chloroform, carbon tetrachloride, carbon disulfide, petroleum ether and oils. Relative density 1.26362. Melting point 17.8 ℃. Boiling point 290.0 deg.c (decomposition). Refractive index 1.4746. Flash point (open cup) 176 ℃. Acute toxicity LD50:31500 mg/kg (rat oral). Glycerol is a backbone component of the triglyceride molecule. When the human body takes in the edible fat, triglyceride in the edible fat is metabolized and decomposed in the body to form glycerol and is stored in fat cells. Thus, the end products of triglyceride metabolism are glycerol and fatty acids. Can be used as solvent, lubricant, medicament and sweetener.
Epidermal growth factor is the earliest growth factor discovered and plays an important role in regulating cell growth, proliferation and differentiation.
The polyglutamic acid is also called natto gum and polyglutamic acid, is a biological polymer which is water-soluble, biodegradable and nontoxic and is prepared by using a microbial fermentation method. Gamma-PGA polyglutamic acid is a viscous substance, and is first found in "natto" -fermented beans. Gamma-PGA polyglutamic acid is a special anionic natural polymer, and the molecular weight of the homo-polyamide (homo-polyamide) gamma-PGA formed by amide bonding (amide linking) between alpha-amino (alpha-amino) and gamma-carboxyl (gamma-carboxyl) is different from 5 ten thousand to 2 million daltons.
The sodium hyaluronate is extracted from rooster comb, or prepared by fermentation of lactococcus lactis, and is white or white-like granule or powder, and has no odor, nitrogen content of 2.8-4.0% and glucuronic acid content of 37.0-51.0% when dried. Is widely used in the field of cosmetics and has the function of moisturizing.
Preferably, the electrolyte solution contains 2.34g of sodium chloride per 1000mL of solution; 5.02g of sodium gluconate; sodium lactate 2.24 g; 0.75g of potassium chloride; 0.30g of magnesium chloride.
Preferably, the compound injection comprises, by weight, vitamin C14%, glutathione 18%, nicotinamide 20%, nonapeptide-112%, mannitol 2%, sorbitol 2%, high methoxyl pectin 1%, propylene glycol alginate 2%, trehalose 2%, glycerol 4%, electrolyte solution 18%, epidermal growth factor 1%, polyglutamic acid 2%, sodium hyaluronate 1%, and hydrolyzed hyaluronic acid 1%.
A preparation method of a compound injection with whitening and anti-aging effects comprises the following steps:
step 1: according to the mass percentage, 1-2% of hydrolyzed hyaluronic acid, 1-6% of mannitol, 1-5% of sorbitol, 1-2% of high methoxyl pectin, 1-3% of polyglutamic acid and 1-2% of sodium hyaluronate are added into an emulsifying pot, then the temperature is raised to 70-90 ℃, and the materials are uniformly stirred to be completely dissolved to form a mixed solution;
step 2: preserving the temperature of the mixed solution in the step 1 for 30-40 min, and then cooling the mixed solution in a stirring state;
and step 3: when the temperature of the mixed solution in the step 2 is reduced to 35-45 ℃, adding 12-40% of vitamin C, 12-30% of glutathione, 10-25% of nicotinamide, 110-24% of nonapeptide, 1-3% of propylene glycol alginate, 1-3% of trehalose, 2-16% of glycerol, 6-20% of electrolyte solution and 1-2% of epidermal growth factor into an emulsifying pot, uniformly stirring to completely dissolve the mixture, standing for 18-24 h after passing detection, filtering and discharging to obtain the compound injection with the whitening and anti-aging effects.
Preferably, the step 3 is performed by filtration using a 0.22 μm filter.
Preferably, the stirring speed in the step 1 is 45 rpm.
Preferably, the stirring speed in the step 2 is 35 rpm.
Compared with the prior art, the invention has the beneficial effects that:
(1) the invention relates to a compound injection with whitening and anti-aging effects and a preparation method thereof, which mainly play a role in shrinking pores, fading fine wrinkles, moisturizing and rejuvenating skin, achieving the three-dimensional function of the face, and have the effects of improving the metabolism of skin cells, conditioning skin microcirculation, conditioning facial qi and blood, beautifying, anti-aging and whitening;
(2) the invention relates to a compound injection with whitening and anti-aging effects and a preparation method thereof, which can promote the repair capability of skin cells, improve the anti-allergy capability of skin, remove wrinkles, whiten and brighten the skin and delay the aging process of the skin cells. Repairing damaged cells and improving the immunity of the cells;
(3) the invention relates to a compound injection with whitening and anti-aging effects and a preparation method thereof, which can promote the metabolism of sugar, fat and protein, can influence the metabolic process of cells, can be converted into easily metabolized acid substances by combining sulfur radicals with free radicals in vivo, thereby accelerating the excretion of the free radicals, being beneficial to reducing the toxic and side effects of chemotherapy and radiotherapy, having no obvious influence on the curative effects of the chemotherapy and the radiotherapy, effectively protecting the functions of liver synthesis, detoxification, hormone inactivation and the like, promoting the metabolism of cholic acid, and being beneficial to the absorption of fat, fat-soluble vitamins and the like by digestive tracts.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
The invention provides a compound injection with whitening and anti-aging effects and a technical scheme of a preparation method thereof, wherein the compound injection comprises the following components in parts by weight: the compound injection with the effects of whitening and resisting ageing comprises, by weight, vitamin C14%, glutathione 18%, nicotinamide 20%, nonapeptide-112%, mannitol 2%, sorbitol 2%, high methoxyl pectin 1%, propylene glycol alginate 2%, trehalose 2%, glycerol 4%, electrolyte solution 18%, epidermal growth factor 1%, polyglutamic acid 2%, sodium hyaluronate 1% and hydrolyzed hyaluronic acid 1%.
Wherein, the electrolyte solution contains 2.34g of sodium chloride in each 1000mL of solution; 5.02g of sodium gluconate; sodium lactate 2.24 g; 0.75g of potassium chloride; 0.30g of magnesium chloride.
A preparation method of a compound injection with whitening and anti-aging effects comprises the following steps:
step 1: according to the mass percentage, 1 percent of hydrolyzed hyaluronic acid, 2 percent of mannitol, 2 percent of sorbitol, 1 percent of high methoxyl pectin, 2 percent of polyglutamic acid and 1 percent of sodium hyaluronate are added into an emulsifying pot, then the temperature is raised to 85 ℃, and the materials are stirred uniformly to be dissolved completely;
step 2: preserving the temperature of the mixed solution in the step 1 for 35min, and then cooling the mixed solution in a stirring state;
and step 3: and (3) when the temperature of the mixed solution in the step (2) is reduced to 37 ℃, adding vitamin C14%, glutathione 18%, nicotinamide 20%, nonapeptide-112%, propylene glycol alginate 2%, trehalose 2%, glycerol 4%, electrolyte solution 18% and epidermal growth factor 1% into an emulsifying pot, uniformly stirring to completely dissolve the mixture, standing for 19h after passing the detection, and filtering and discharging to obtain the compound injection with the whitening and anti-aging effects.
Example 2
The invention provides a compound injection with whitening and anti-aging effects and a technical scheme of a preparation method thereof, wherein the compound injection comprises the following components in parts by weight: the compound injection with the effects of whitening and resisting ageing comprises, by weight, vitamin C28%, glutathione 17%, nicotinamide 14%, nonapeptide-114%, mannitol 2%, sorbitol 2%, high methoxyl pectin 1%, propylene glycol alginate 2%, trehalose 1%, glycerol 2%, electrolyte solution 12%, epidermal growth factor 2%, polyglutamic acid 1%, sodium hyaluronate 1% and hydrolyzed hyaluronic acid 1%.
Wherein, the electrolyte solution contains 2.34g of sodium chloride in each 1000mL of solution; 5.02g of sodium gluconate; sodium lactate 2.24 g; 0.75g of potassium chloride; 0.30g of magnesium chloride.
A preparation method of a compound injection with whitening and anti-aging effects comprises the following steps:
step 1: according to the mass percentage, 1 percent of hydrolyzed hyaluronic acid, 2 percent of mannitol, 2 percent of sorbitol, 1 percent of high methoxyl pectin, 1 percent of polyglutamic acid and 1 percent of sodium hyaluronate are added into an emulsifying pot, then the temperature is raised to 86 ℃, and the materials are stirred uniformly to be dissolved completely;
step 2: preserving the heat of the mixed solution in the step 1 for 38min, and then cooling the mixed solution in a stirring state;
and step 3: and (3) when the temperature of the mixed solution in the step (2) is reduced to 35 ℃, adding vitamin C28%, glutathione 17%, nicotinamide 14%, nonapeptide-114%, propylene glycol alginate 2%, trehalose 1%, glycerol 2%, electrolyte solution 12% and epidermal growth factor 2% into an emulsifying pot, uniformly stirring to completely dissolve the mixture, standing for 19h after passing the detection, and filtering and discharging to obtain the compound injection with the whitening and anti-aging effects.
Example 3
The invention provides a compound injection with whitening and anti-aging effects and a technical scheme of a preparation method thereof, wherein the compound injection comprises the following components in parts by weight: the compound injection with the effects of whitening and resisting ageing comprises, by weight, vitamin C16%, glutathione 14%, nicotinamide 18%, nonapeptide-110%, mannitol 4%, sorbitol 4%, high methoxyl pectin 1%, propylene glycol alginate 2%, trehalose 2%, glycerol 11%, electrolyte solution 12%, epidermal growth factor 1%, polyglutamic acid 2%, sodium hyaluronate 2% and hydrolyzed hyaluronic acid 1%.
Wherein, the electrolyte solution contains 2.34g of sodium chloride in each 1000mL of solution; 5.02g of sodium gluconate; sodium lactate 2.24 g; 0.75g of potassium chloride; 0.30g of magnesium chloride.
A preparation method of a compound injection with whitening and anti-aging effects comprises the following steps:
step 1: according to the mass percentage, 1 percent of hydrolyzed hyaluronic acid, 4 percent of mannitol, 4 percent of sorbitol, 1 percent of high methoxyl pectin, 2 percent of polyglutamic acid and 2 percent of sodium hyaluronate are added into an emulsifying pot, then the temperature is raised to 88 ℃, and the materials are stirred uniformly to be dissolved completely;
step 2: preserving the temperature of the mixed solution in the step 1 for 35min, and then cooling the mixed solution in a stirring state;
and step 3: and (3) when the temperature of the mixed solution in the step (2) is reduced to 36 ℃, adding vitamin C16%, glutathione 14%, nicotinamide 18%, nonapeptide-110%, propylene glycol alginate 2%, trehalose 2%, glycerol 4%, electrolyte solution 12% and epidermal growth factor 1% into an emulsifying pot, uniformly stirring to completely dissolve the mixture, standing for 19h after passing the detection, and filtering and discharging to obtain the compound injection with the whitening and anti-aging effects.
Comparative example 1
Vitamins, glutathione, nicotinamide and nonapeptide-1 are not added in the components of the compound injection, and the rest components and the preparation method thereof are completely the same as the embodiment 1.
The compound injection is prepared by the methods of the examples and the comparative examples respectively, except the components are different, the preparation methods are the same, and the test results are shown in table 1:
table 1 test results of the compounded injection
As can be seen from table 1, the compound injection provided by the invention has the functions of shrinking pores, fading fine wrinkles, moisturizing skin, being full in outline and three-dimensional face by adding the vitamins, glutathione, nicotinamide and nonapeptide-1 into the injection, has the effects of improving skin cell metabolism, conditioning skin microcirculation, conditioning facial qi and blood, beautifying, resisting aging and whitening, promoting the repair capacity of skin cells, improving the anti-allergy capacity of skin, removing wrinkles, whitening and brightening the skin, and delaying the aging process of skin cells. Repairing damaged cells and improving the immunity of the cells; the compound can promote the metabolism of sugar, fat and protein, can influence the metabolic process of cells, can be combined with free radicals in vivo through sulfur radicals, and can be converted into acid substances easy to metabolize, so that the excretion of the free radicals is accelerated, the toxic and side effects of chemotherapy and radiotherapy can be reduced, the curative effects of the chemotherapy and the radiotherapy are not obviously influenced, the functions of liver synthesis, detoxification, hormone inactivation and the like are effectively protected, the metabolism of bile acid is promoted, and the absorption of fat, fat-soluble vitamins and the like by digestive tracts is facilitated.
The compound injection prepared in the above examples is tested, and the used components meet the provisions of the defense method No. 229. The hygiene indicators are shown in table 2 below:
from table 2, the standards of the compound injections in examples 1 to 3 that meet the hygienic standards are obtained, and the hygienic standards are determined according to the relevant regulations in (QB/T2660-2004 standards for the light industry of the people's republic of china), and can be used with confidence.
In the description of the present invention, it is to be understood that the terms "coaxial", "bottom", "one end", "top", "middle", "other end", "upper", "one side", "top", "inner", "front", "center", "two ends", etc., indicate orientations or positional relationships and are used merely for convenience of description and for simplicity of description, but do not indicate or imply that the device or element being referred to must have a particular orientation, be constructed and operated in a particular orientation, and thus, should not be construed as limiting the present invention.
In the present invention, unless otherwise expressly specified or limited, the terms "mounted," "disposed," "connected," "secured," "screwed" and the like are to be construed broadly, e.g., as meaning fixedly connected, detachably connected, or integrally formed; can be mechanically or electrically connected; the terms may be directly connected or indirectly connected through an intermediate, and may be communication between two elements or interaction relationship between two elements, unless otherwise specifically limited, and the specific meaning of the terms in the present invention will be understood by those skilled in the art according to specific situations.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (7)
1. The compound injection with the effects of whitening and resisting ageing is characterized by comprising, by weight, vitamin C12-40%, glutathione 12-30%, nicotinamide 10-25%, nonapeptide-110-24%, mannitol 1-6%, sorbitol 1-5%, high methoxyl pectin 1-2%, propylene glycol alginate 1-3%, trehalose 1-3%, glycerol 2-16%, electrolyte solution 6-20%, epidermal growth factor 1-2%, polyglutamic acid 1-3%, sodium hyaluronate 1-2%, and hydrolyzed hyaluronic acid 1-2%.
2. The compound injection with the whitening and anti-aging effects as claimed in claim 1, is characterized in that: the electrolyte solution contains 2.34g of sodium chloride in each 1000mL of solution; 5.02g of sodium gluconate; sodium lactate 2.24 g; 0.75g of potassium chloride; 0.30g of magnesium chloride.
3. The compound injection with the whitening and anti-aging effects as claimed in claim 1, is characterized in that: the components and weight percentage of the compound injection comprise vitamin C14%, glutathione 18%, nicotinamide 20%, nonapeptide-112%, mannitol 2%, sorbitol 2%, high methoxyl pectin 1%, propylene glycol alginate 2%, trehalose 2%, glycerin 4%, electrolyte solution 18%, epidermal growth factor 1%, polyglutamic acid 2%, sodium hyaluronate 1%, and hydrolyzed hyaluronic acid 1%.
4. The preparation method of the compound injection with the effects of whitening and resisting aging according to claim 1, which is characterized by comprising the following steps:
step 1: according to the mass percentage, 1-2% of hydrolyzed hyaluronic acid, 1-6% of mannitol, 1-5% of sorbitol, 1-2% of high methoxyl pectin, 1-3% of polyglutamic acid and 1-2% of sodium hyaluronate are added into an emulsifying pot, then the temperature is raised to 70-90 ℃, and the materials are uniformly stirred to be completely dissolved to form a mixed solution;
step 2: preserving the temperature of the mixed solution in the step 1 for 30-40 min, and then cooling the mixed solution in a stirring state;
and step 3: when the temperature of the mixed solution in the step 2 is reduced to 35-45 ℃, adding 12-40% of vitamin C, 12-30% of glutathione, 10-25% of nicotinamide, 110-24% of nonapeptide, 1-3% of propylene glycol alginate, 1-3% of trehalose, 2-16% of glycerol, 6-20% of electrolyte solution and 1-2% of epidermal growth factor into an emulsifying pot, uniformly stirring to completely dissolve the mixture, standing for 18-24 h after passing detection, filtering and discharging to obtain the compound injection with the whitening and anti-aging effects.
5. The preparation method of the compound injection with whitening and anti-aging effects as claimed in claim 4, wherein a 0.22 μm filter is adopted for filtration in the step 3.
6. The preparation method of the compound injection with the effects of whitening and anti-aging according to claim 4, wherein the stirring speed in the step 1 is 45 revolutions per minute.
7. The preparation method of the compound injection with the effects of whitening and anti-aging according to claim 4, wherein the stirring speed in the step 2 is 35 rpm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110534448.1A CN113143791A (en) | 2021-05-17 | 2021-05-17 | Compound injection with whitening and anti-aging effects and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110534448.1A CN113143791A (en) | 2021-05-17 | 2021-05-17 | Compound injection with whitening and anti-aging effects and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113143791A true CN113143791A (en) | 2021-07-23 |
Family
ID=76876333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110534448.1A Pending CN113143791A (en) | 2021-05-17 | 2021-05-17 | Compound injection with whitening and anti-aging effects and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113143791A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520017A (en) * | 2013-10-22 | 2014-01-22 | 易金阳 | Wrinkle-removing, anti-ageing, skin-activating, restoring and whitening composition |
| CN106821915A (en) * | 2015-11-27 | 2017-06-13 | 朱延升 | A kind of anti-ageing cleawhite over-night essences |
| CN107184427A (en) * | 2017-04-17 | 2017-09-22 | 杭州惠博士健康产业有限公司 | A kind of cooperative compositions and application containing polyglutamic acid and hyaluronic acid |
| CN107213166A (en) * | 2017-05-26 | 2017-09-29 | 海南博鳌银丰康养国际医院有限公司 | Umbilical cord blood plasma parenteral solution of effect and preparation method thereof is repaired with anti-ageing and organ |
| CN111686039A (en) * | 2020-07-03 | 2020-09-22 | 广州暨创医美生物科技有限公司 | Whitening and skin-brightening composition and preparation method thereof |
-
2021
- 2021-05-17 CN CN202110534448.1A patent/CN113143791A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520017A (en) * | 2013-10-22 | 2014-01-22 | 易金阳 | Wrinkle-removing, anti-ageing, skin-activating, restoring and whitening composition |
| CN106821915A (en) * | 2015-11-27 | 2017-06-13 | 朱延升 | A kind of anti-ageing cleawhite over-night essences |
| CN107184427A (en) * | 2017-04-17 | 2017-09-22 | 杭州惠博士健康产业有限公司 | A kind of cooperative compositions and application containing polyglutamic acid and hyaluronic acid |
| CN107213166A (en) * | 2017-05-26 | 2017-09-29 | 海南博鳌银丰康养国际医院有限公司 | Umbilical cord blood plasma parenteral solution of effect and preparation method thereof is repaired with anti-ageing and organ |
| CN111686039A (en) * | 2020-07-03 | 2020-09-22 | 广州暨创医美生物科技有限公司 | Whitening and skin-brightening composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114947141B (en) | Composition with skin beautifying effect and application thereof | |
| CN104041828B (en) | Black matrimony vine whitening spot-removing sheet | |
| CN101703287A (en) | Donkey-hide gelatin drink and preparation method thereof | |
| CN112772813A (en) | Compound peptide solid beverage capable of improving immunity and relieving fatigue and preparation method thereof | |
| CN109431854A (en) | A kind of bFGF acne hole maintenance freeze-dried powder preparation and preparation method thereof | |
| CN108743500A (en) | Not only oral administration but also can external application beautifying face and moistering lotion compound peptide functional food and preparation method thereof | |
| CN105211862A (en) | A kind of nutrition bag being applicable to women's moisturizing, beauty face-whitening-nourishing | |
| CN109260116A (en) | It is a kind of containing plant extracts to peptide skin base solution and its production technology | |
| CN103381136A (en) | Edible cosmetics and preparation method thereof | |
| CN110339398A (en) | One kind Amvisc containing amino acid and preparation method thereof | |
| CN113018230A (en) | Composition and preparation method and application thereof | |
| CN112137054A (en) | Collagen tripeptide sour cherry jelly and preparation method thereof | |
| CN113521258A (en) | Tissue injection for improving aging | |
| CN107115448B (en) | Traditional Chinese medicine composition with whitening and anti-aging effects and preparation method and application thereof | |
| CN102008099B (en) | Red date beautifying beverage | |
| CN109430883A (en) | Free peptide extract of marine fishes and its preparation method and application | |
| CN107648585A (en) | A kind of anti-ageing anti-wrinkle Essence containing white fungus, aurantiamarin and soluble protein | |
| CN113143791A (en) | Compound injection with whitening and anti-aging effects and preparation method thereof | |
| CN116509750A (en) | Composite fish collagen mask liquid and preparation method thereof | |
| CN110585079A (en) | Radiation-resistant composition containing food-borne peptide and radiation-resistant emulsion thereof | |
| CN110771902A (en) | Composite polypeptide powder and application thereof | |
| CN110897933A (en) | Cell repair essence for facial care | |
| CN109172492A (en) | A kind of fast more frost and preparation method thereof | |
| CN111067845A (en) | Natural plant multi-effect repair mask and preparation method thereof | |
| CN101297705B (en) | Compound Tibet sheep placenta capsule for removing wrinkle and resisting aging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210723 |